Home › Companies › Protagonist Therapeutics, Inc. › 2025-2026

Protagonist Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Protagonist Therapeutics, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated October 25, 2026.

5Ballot items
361Asset managers
2,507Fund votes
June 17, 2026Meeting date

Results at a glance

Meeting of June 17, 2026: 5 items on Protagonist Therapeutics, Inc.’s Form 8-K, filed June 18, 2026: 3 approved · 2 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Protagonist Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Protagonist Therapeutics, Inc.

These tallies are Protagonist Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Protagonist Therapeutics, Inc. — official shareholder meeting results, meeting held June 17, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Dinesh V. Patel, Ph.D.	48,714,702	--	--	7,875,311	2,819,234	86%	Not verified	—
Elect Director: Lewis T. "Rusty" Williams, M.D., Ph.D.	45,371,193	--	--	11,218,820	2,819,234	80%	Not verified	—
2. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers	53,412,559	3,164,702	12,752	--	2,819,234	94%	Approved	—
3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026	59,371,487	28,221	9,539	--	--	99.9%	Approved	—
4. To approve the adoption of the Company's 2026 Equity Incentive Plan	47,745,562	8,826,703	17,748	--	2,819,234	84%	Approved	—

Source: Protagonist Therapeutics, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.

How asset managers voted at the Protagonist Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 361 asset managers that disclosed a Protagonist Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Dinesh V. Patel, Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%

FOR: 48,714,702WITHHELD: 7,875,311

Details: description as filed, official tally, votes by 103 asset managers

Description as filed by funds: To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Dinesh V. Patel, Ph.D.

Protagonist Therapeutics, Inc.’s own tally for this item (“Elect Director: Dinesh V. Patel, Ph.D.”): 48,714,702 for, 7,875,311 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 103 asset managers below reported 25,050,958 for, 1,620,821 withheld, 357,599 abstained.

FOR

FOR: 25,050,958ABSTAIN: 357,599WITHHOLD: 1,620,821

Largest asset managers voting on “To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholder” at Protagonist Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	8,196,775	56	0	For
BlackRock	5,991,934	0	0	For
Fidelity	2,154,091	0	0	For
Invesco	1,570,687	0	0	For
T. Rowe Price	1,349,085	0	0	For
JANUS INVESTMENT FUND	978,011	0	0	For
State Street	773,456	0	890	For
Prudential/PGIM	484,616	0	4,528	For
Charles Schwab	482,250	0	0	For
American Century	0	0	412,809	Withhold
Jackson National	188,307	198,749	0	Mixed
Lord Abbett	343,358	0	0	For
Voya	304,405	0	0	For
Legg Mason	235,216	0	6,209	For
Hartford	226,240	0	0	For
Putnam	172,647	0	0	For
Victory Capital	544	0	161,490	Withhold
Equitable	146,029	0	0	For
DRIEHAUS MUTUAL FUNDS	0	0	138,752	Withhold
Brighthouse	107,116	0	29,835	Mixed
Columbia Threadneedle	133,815	0	0	For
JPMorgan	133,312	0	0	For
John Hancock	51,440	73,361	0	Mixed
TIAA	118,095	0	0	For
AIG/SunAmerica	0	0	106,616	Withhold

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

2. Elect Director: Lewis T. "Rusty" Williams, M.D., Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 8 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD

FOR: 45,371,193WITHHELD: 11,218,820

Details: description as filed, official tally, votes by 103 asset managers

Protagonist Therapeutics, Inc.’s own tally for this item (“Elect Director: Lewis T. "Rusty" Williams, M.D., Ph.D.”): 45,371,193 for, 11,218,820 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 103 asset managers below reported 22,858,860 for, 3,225,193 withheld, 945,325 abstained.

FOR

FOR: 22,858,860ABSTAIN: 945,325WITHHOLD: 3,225,193

Largest asset managers voting on “To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholder” at Protagonist Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	8,196,754	77	0	For
BlackRock	5,438,131	553,803	0	Mixed
Fidelity	2,154,091	0	0	For
Invesco	1,570,687	0	0	For
T. Rowe Price	0	0	1,349,085	Withhold
JANUS INVESTMENT FUND	978,011	0	0	For
State Street	773,456	0	890	For
Prudential/PGIM	484,616	0	4,528	For
Charles Schwab	482,250	0	0	For
American Century	0	0	412,809	Withhold
Jackson National	186,952	200,104	0	Mixed
Lord Abbett	343,358	0	0	For
Voya	304,405	0	0	For
Legg Mason	235,216	0	6,209	For
Hartford	226,240	0	0	For
Putnam	172,647	0	0	For
Victory Capital	544	0	161,490	Withhold
Equitable	82,788	0	63,241	Mixed
DRIEHAUS MUTUAL FUNDS	0	0	138,752	Withhold
Brighthouse	94,311	0	42,640	Mixed
Columbia Threadneedle	133,815	0	0	For
JPMorgan	133,312	0	0	For
John Hancock	27,444	97,357	0	Mixed
TIAA	0	0	118,095	Withhold
AIG/SunAmerica	0	0	106,616	Withhold

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

3. 4. To approve the adoption of the Company's 2026 Equity Incentive Plan

Official result Fund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

84% Approved · of votes cast

FOR 84%AGAINST

FOR: 47,745,562AGAINST: 8,826,703

Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: TO APPROVE THE ADOPTION OF THE COMPANY'S 2026 EQUITY INCENTIVE PLAN.

Protagonist Therapeutics, Inc.’s own tally for this item (“4. To approve the adoption of the Company's 2026 Equity Incentive Plan”): 47,745,562 for, 8,826,703 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 104 asset managers voting on “TO APPROVE THE ADOPTION OF THE COMPANY'S 2026 EQUITY INCENTIVE PLAN.” at Protagonist Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	8,179,222	17,609	For
BlackRock	5,991,934	0	For
Fidelity	2,154,091	0	For
Invesco	1,570,687	0	For
T. Rowe Price	1,349,085	0	For
JANUS INVESTMENT FUND	978,011	0	For
State Street	772,559	1,787	For
Prudential/PGIM	481,376	7,768	For
Charles Schwab	482,250	0	For
American Century	0	412,809	Against
Jackson National	188,307	198,749	Mixed
Lord Abbett	343,358	0	For
Voya	0	304,405	Against
Legg Mason	235,216	6,209	For
Hartford	226,240	0	For
Putnam	6,532	172,647	Against
Victory Capital	544	161,490	Against
Equitable	146,029	0	For
DRIEHAUS MUTUAL FUNDS	0	138,752	Against
Columbia Threadneedle	133,815	0	For
JPMorgan	133,312	0	For
John Hancock	51,440	73,361	Mixed
TIAA	118,095	0	For
AIG/SunAmerica	0	106,616	Against
QUANTITATIVE MASTER SERIES LLC	94,595	0	For

Fund voting reports, all 104 managers: 24,438,127 for, 2,451,413 against, 14,349 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 6 asset managers voting on “TO APPROVE THE ADOPTION OF THE COMPANY'S 2026 EQUITY INCENTIVE PLAN.” at Protagonist Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Duquesne Family Office LLC	159,700	For
NEXTBio Capital Management LP	152,866	For
Vident Advisory, LLC	4,698	For
UNITED CAPITAL FINANCIAL ADVISORS, LLC	4,292	For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	504	For
Boltwood Capital Management	140	For

Institutional-manager reports, all 6 managers: 322,200 for.

4. 2. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%

FOR: 53,412,559AGAINST: 3,164,702

Details: description as filed, official tally, votes by 361 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.

Protagonist Therapeutics, Inc.’s own tally for this item (“2. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers”): 53,412,559 for, 3,164,702 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports: 106 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at Protagonist Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	8,196,822	9	0	For
BlackRock	5,991,934	0	0	For
Fidelity	2,154,091	0	0	For
Invesco	457,668	1,113,019	0	Mixed
T. Rowe Price	1,349,085	0	0	For
JANUS INVESTMENT FUND	978,011	0	0	For
State Street	774,025	321	0	For
Prudential/PGIM	489,144	0	0	For
Charles Schwab	482,250	0	0	For
American Century	412,809	0	0	For
Jackson National	200,104	186,952	0	Mixed
Lord Abbett	343,358	0	0	For
Voya	304,405	0	0	For
Legg Mason	241,425	0	0	For
Hartford	226,240	0	0	For
Putnam	179,179	0	0	For
Victory Capital	162,034	0	0	For
Equitable	146,029	0	0	For
DRIEHAUS MUTUAL FUNDS	138,752	0	0	For
Brighthouse	33,330	94,311	9,310	Mixed
Columbia Threadneedle	133,815	0	0	For
JPMorgan	133,312	0	0	For
John Hancock	124,801	0	0	For
TIAA	118,095	0	0	For
AIG/SunAmerica	106,616	0	0	For

Fund voting reports, all 106 managers: 25,550,429 for, 1,483,388 against, 9,310 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 284 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at Protagonist Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
RTW INVESTMENTS, LP	5,059,053	0	For
FARALLON CAPITAL MANAGEMENT, L.L.C.	4,779,080	0	For
Janus Henderson	3,439,829	0	For
Wellington	2,703,511	0	For
BlackRock	1,834,489	31,019	For
State Street	1,863,089	321	For
T. Rowe Price	1,749,645	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,679,699	0	For
Invesco	30,938	1,530,435	Against
Woodline Partners LP	1,219,306	0	For
ADAR1 Capital Management, LLC	908,483	0	For
JENNISON ASSOCIATES LLC	835,481	0	For
Fidelity	666,340	0	For
Clearbridge Investments, LLC	623,901	0	For
Charles Schwab	553,717	0	For
Northern Trust	522,701	4,088	For
PICTET ASSET MANAGEMENT SA	516,333	0	For
Vanguard	503,454	0	For
American Century	461,158	0	For
Voya	418,589	0	For
LORD, ABBETT & CO. LLC	377,236	0	For
PRINCIPAL GLOBAL INVESTORS	369,014	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	361,142	0	For
Hood River Capital Management LLC	348,171	0	For
Focus Partners Wealth	334,341	164	For

Institutional-manager reports, all 284 managers: 38,002,679 for, 2,644,148 against, 139 abstained, 3,689 not voted. Showing the 25 largest; see all in the interactive database.

5. 3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%

FOR: 59,371,487AGAINST: 28,221

Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

Protagonist Therapeutics, Inc.’s own tally for this item (“3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026”): 59,371,487 for, 28,221 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 106 asset managers below reported 27,009,492 for, 24,325 against, 9,310 abstained.

FOR

FOR: 27,009,492AGAINST: 24,325ABSTAIN: 9,310

Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FO” at Protagonist Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	8,196,831	0	For
BlackRock	5,991,934	0	For
Fidelity	2,154,091	0	For
Invesco	1,570,687	0	For
T. Rowe Price	1,349,085	0	For
JANUS INVESTMENT FUND	978,011	0	For
State Street	774,346	0	For
Prudential/PGIM	489,144	0	For
Charles Schwab	482,250	0	For
American Century	412,809	0	For
Jackson National	387,056	0	For
Lord Abbett	343,358	0	For
Voya	304,405	0	For
Legg Mason	241,425	0	For
Hartford	226,240	0	For
Putnam	179,179	0	For
Victory Capital	162,034	0	For
Equitable	146,029	0	For
DRIEHAUS MUTUAL FUNDS	138,752	0	For
Brighthouse	127,641	9,310	Mixed
Columbia Threadneedle	133,815	0	For
JPMorgan	133,312	0	For
John Hancock	124,801	0	For
TIAA	118,095	0	For
AIG/SunAmerica	106,616	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

Largest Protagonist Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 64,227,057 shares outstanding at the time of that meeting.

Fund voting reports: top Protagonist Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	12.76%
2	BlackRock	9.33%
3	Fidelity	3.35%
4	Invesco	2.45%
5	T. Rowe Price	2.10%
6	JANUS INVESTMENT FUND	1.52%
7	State Street	1.21%
8	Prudential/PGIM	0.76%
9	Charles Schwab	0.75%
10	American Century	0.64%

Institutional-manager reports: top Protagonist Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2025-2026
#	Asset manager	% of shares outstanding
1	RTW INVESTMENTS, LP	7.88%
2	FARALLON CAPITAL MANAGEMENT, L.L.C.	7.44%
3	Janus Henderson	5.36%
4	Wellington	4.21%
5	BlackRock	2.90%
6	State Street	2.90%
7	T. Rowe Price	2.72%
8	GEODE CAPITAL MANAGEMENT, LLC	2.62%
9	Invesco	2.43%
10	Woodline Partners LP	1.90%

Reported Protagonist Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Protagonist Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	15.23%	13F
Entities affiliated with BlackRock, Inc.	13.35%	DEF14A
Farallon Capital Management, L.L.C.	10.02%	13G
Entities affiliated with Farallon Partners, L.L.C.	9.97%	DEF14A
Entities affiliated with The Vanguard Group	8.43%	DEF14A
Vanguard Group	8.43%	13F
Entities affiliated with RTW Investments, L.P.	7.88%	DEF14A
RTW Investments, LP	7.88%	13G
Wellington Management	5.60%	13F
Vanguard Portfolio Management	5.50%	13G

Percentages above are of 64,227,057 shares outstanding, as reported by Protagonist Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Protagonist Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.

At Protagonist Therapeutics, Inc.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 361 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 2,507 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — Protagonist Therapeutics, Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Protagonist Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.

Protagonist Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.